USE OF LORATADINE IN PREGNANCY
Date of issue: March 2026, Version: 4
Loratadine is a non-sedating antihistamine used for the symptomatic relief of allergic conditions, including rhinitis (hay fever) and chronic idiopathic urticaria.
The available published data do not suggest an increased risk of miscarriage, infant congenital malformation, stillbirth or preterm delivery following in utero exposure to loratadine in pregnancy, and do not provide convincing evidence of an association with small for gestational age infants. However, some of the available data are methodologically limited, meaning further research is required. There are no data regarding infant neurodevelopment following in utero exposure to loratadine.
If local topical therapy fails to control symptoms, oral antihistamines can be considered for use in pregnancy. Non-sedating antihistamines tend to be used first-line due to potential risks associated with maternal drowsiness, with cetirizine and loratadine generally being preferred due to a larger volume of reassuring human pregnancy data.
Exposure to loratadine at any stage of pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.